Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

De Falco V, Carlomagno F, Li HY, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10. Review.

PMID:
28911727
2.

Identifying subtype-specific associations between gene expression and DNA methylation profiles in breast cancer.

Lee G, Bang L, Kim SY, Kim D, Sohn KA.

BMC Med Genomics. 2017 May 24;10(Suppl 1):28. doi: 10.1186/s12920-017-0268-z.

3.

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L.

Oncol Rep. 2017 Apr;37(4):2215-2226. doi: 10.3892/or.2017.5494. Epub 2017 Mar 8.

4.

RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.

Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ.

Cell Rep. 2016 Dec 20;17(12):3319-3332. doi: 10.1016/j.celrep.2016.11.061.

5.

LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.

Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, Shao L, Li A, Yang N, Han X, Pan B, Zhang Z, Sun L, Sun Y.

Oncotarget. 2016 Dec 6;7(49):81452-81462. doi: 10.18632/oncotarget.13263.

6.

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A.

Oncotarget. 2016 Dec 6;7(49):80543-80553. doi: 10.18632/oncotarget.11826.

7.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Oncotarget. 2016 May 3;7(18):26465-79. doi: 10.18632/oncotarget.8417.

8.

ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.

Si X, Liu Y, Lv J, Ding H, Zhang XA, Shao L, Yang N, Cheng H, Sun L, Zhu D, Yang Y, Li A, Han X, Sun Y.

Oncotarget. 2016 Apr 12;7(15):20966-80. doi: 10.18632/oncotarget.8038.

9.

EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.

De Andrade JP, Park JM, Gu VW, Woodfield GW, Kulak MV, Lorenzen AW, Wu VT, Van Dorin SE, Spanheimer PM, Weigel RJ.

Mol Cancer Ther. 2016 Mar;15(3):503-11. doi: 10.1158/1535-7163.MCT-15-0548-T. Epub 2016 Feb 1.

10.

Thyroid C-Cell Biology and Oncogenic Transformation.

Cote GJ, Grubbs EG, Hofmann MC.

Recent Results Cancer Res. 2015;204:1-39. doi: 10.1007/978-3-319-22542-5_1. Review.

11.

Cis and trans RET signaling control the survival and central projection growth of rapidly adapting mechanoreceptors.

Fleming MS, Vysochan A, Paixão S, Niu J, Klein R, Savitt JM, Luo W.

Elife. 2015 Apr 2;4:e06828. doi: 10.7554/eLife.06828.

12.

Quantitative analysis of receptor tyrosine kinase-effector coupling at functionally relevant stimulus levels.

Li S, Bhave D, Chow JM, Riera TV, Schlee S, Rauch S, Atanasova M, Cate RL, Whitty A.

J Biol Chem. 2015 Apr 17;290(16):10018-36. doi: 10.1074/jbc.M114.602268. Epub 2015 Jan 29.

13.

Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.

Alao JP, Michlikova S, Dinér P, Grøtli M, Sunnerhagen P.

BMC Cancer. 2014 Nov 20;14:853. doi: 10.1186/1471-2407-14-853.

14.

Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.

Spanheimer PM, Park JM, Askeland RW, Kulak MV, Woodfield GW, De Andrade JP, Cyr AR, Sugg SL, Thomas A, Weigel RJ.

Clin Cancer Res. 2014 Apr 15;20(8):2115-25. doi: 10.1158/1078-0432.CCR-13-2221. Epub 2014 Feb 13.

15.

Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer.

Morandi A, Isacke CM.

Breast Cancer Res. 2014 Jan 28;16(1):301. doi: 10.1186/bcr3608.

16.

Central role of RET in thyroid cancer.

Santoro M, Carlomagno F.

Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a009233. doi: 10.1101/cshperspect.a009233. Review.

17.

The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways.

Samaan S, Tranchevent LC, Dardenne E, Polay Espinoza M, Zonta E, Germann S, Gratadou L, Dutertre M, Auboeuf D.

Nucleic Acids Res. 2014 Feb;42(4):2197-207. doi: 10.1093/nar/gkt1216. Epub 2013 Nov 25.

18.

Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.

Spanheimer PM, Cyr AR, Gillum MP, Woodfield GW, Askeland RW, Weigel RJ.

Ann Surg. 2014 Apr;259(4):793-9. doi: 10.1097/SLA.0b013e3182a6f552.

19.

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.

Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, Macleod KK, Schlederer M, Lienhard S, Kenner L, Torres-Arzayus MI, Hynes NE.

EMBO Mol Med. 2013 Sep;5(9):1335-50. doi: 10.1002/emmm.201302625. Epub 2013 Jul 19.

20.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.

Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6.

Supplemental Content

Support Center